Abstract
Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment of psoriatic arthritis patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs, but not for those with uncontrolled skin lesions, nor with axial involvement. In this review, we will try to interpret such a differential efficacy of abatacept on the psoriatic arthritis clinical domains, on the basis of its differential effectiveness on the diverse T-cell subsets at different sites. Clinical and biological profiles of possible responders to abatacept will be provided.
| Original language | English |
|---|---|
| Pages (from-to) | 807-821 |
| Number of pages | 15 |
| Journal | Immunotherapy |
| Volume | 10 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Jul 1 2018 |
Keywords
- abatacept
- CD28
- CTLA-4
- CTLA4Ig
- enthesitis
- obesity
- psoriasis
- psoriatic arthritis
- T cells
- therapy
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology